The company is currently focused on developing a small peptide (KIT2014) for the treatment of cystic fibrosis, which has been designated as an Orphan Drug by the European Medicines Agency. Kither Biotech is also developing a molecule (CL27) for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma, which is in the pre-clinical phase of development. The company's goal is to provide treatments for respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary diseases, allergic asthma, and idiopathic pulmonary fibrosis, which currently have unmet medical needs.